David Reynolds, LoQus23 Therapeutics CEO

UK biotech bags $43M in Se­ries A to move Hunt­ing­ton's drug in­to first hu­man study

Lo­Qus23 Ther­a­peu­tics has se­cured £35 mil­lion ($43 mil­lion) in a Se­ries A fundraise led by For­bion and backed by the ven­ture arm of No­var­tis to …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA